Treatment of 'poor risk' acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside

E. P. Balaban, J. V. Cox, N. R. Schneider, C. A. Harth, B. B. Haley, R. Sheehan, E. P. Frenkel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

There is currently little experience using a continuous intravenous infusion of low-dose cytosine arabinoside (LDARA-C) in the treatment of acute nonlymphocytic leukemia (ANLL). We report the results in 12 patients with ANLL described as either relapsed ANLL, ANLL with a preceding myelodysplastic phase, or ANLL in the elderly treated with 14 days of continuous intravenous LDARA-C (20 mg/m2/day). Complete responses (CR) were seen in five patients (42%) and partial responses (PR) in three patients (25%). Treatment resulted in overall and clonal cytoreduction, which was evident by serial bone marrow exams and bone marrow cytogenetic analysis. The ability to obtain a CR correlated with the finding of a low initial marrow cellularity (P < .05). This study finds that continuous intravenous infusion of LDARA-C for ANLL can achieve response rates comparable to standard induction programs in a subset of patients traditionally defined as have a poor prognosis.

Original languageEnglish (US)
Pages (from-to)79-84
Number of pages6
JournalAmerican Journal of Hematology
Volume29
Issue number2
StatePublished - 1988

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Bone Marrow
Intravenous Infusions
Therapeutics
Cytogenetic Analysis
Bone and Bones

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of 'poor risk' acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside. / Balaban, E. P.; Cox, J. V.; Schneider, N. R.; Harth, C. A.; Haley, B. B.; Sheehan, R.; Frenkel, E. P.

In: American Journal of Hematology, Vol. 29, No. 2, 1988, p. 79-84.

Research output: Contribution to journalArticle

Balaban, E. P. ; Cox, J. V. ; Schneider, N. R. ; Harth, C. A. ; Haley, B. B. ; Sheehan, R. ; Frenkel, E. P. / Treatment of 'poor risk' acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside. In: American Journal of Hematology. 1988 ; Vol. 29, No. 2. pp. 79-84.
@article{7511c1fcf56e4651865bcda2a59d7b60,
title = "Treatment of 'poor risk' acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside",
abstract = "There is currently little experience using a continuous intravenous infusion of low-dose cytosine arabinoside (LDARA-C) in the treatment of acute nonlymphocytic leukemia (ANLL). We report the results in 12 patients with ANLL described as either relapsed ANLL, ANLL with a preceding myelodysplastic phase, or ANLL in the elderly treated with 14 days of continuous intravenous LDARA-C (20 mg/m2/day). Complete responses (CR) were seen in five patients (42{\%}) and partial responses (PR) in three patients (25{\%}). Treatment resulted in overall and clonal cytoreduction, which was evident by serial bone marrow exams and bone marrow cytogenetic analysis. The ability to obtain a CR correlated with the finding of a low initial marrow cellularity (P < .05). This study finds that continuous intravenous infusion of LDARA-C for ANLL can achieve response rates comparable to standard induction programs in a subset of patients traditionally defined as have a poor prognosis.",
author = "Balaban, {E. P.} and Cox, {J. V.} and Schneider, {N. R.} and Harth, {C. A.} and Haley, {B. B.} and R. Sheehan and Frenkel, {E. P.}",
year = "1988",
language = "English (US)",
volume = "29",
pages = "79--84",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of 'poor risk' acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside

AU - Balaban, E. P.

AU - Cox, J. V.

AU - Schneider, N. R.

AU - Harth, C. A.

AU - Haley, B. B.

AU - Sheehan, R.

AU - Frenkel, E. P.

PY - 1988

Y1 - 1988

N2 - There is currently little experience using a continuous intravenous infusion of low-dose cytosine arabinoside (LDARA-C) in the treatment of acute nonlymphocytic leukemia (ANLL). We report the results in 12 patients with ANLL described as either relapsed ANLL, ANLL with a preceding myelodysplastic phase, or ANLL in the elderly treated with 14 days of continuous intravenous LDARA-C (20 mg/m2/day). Complete responses (CR) were seen in five patients (42%) and partial responses (PR) in three patients (25%). Treatment resulted in overall and clonal cytoreduction, which was evident by serial bone marrow exams and bone marrow cytogenetic analysis. The ability to obtain a CR correlated with the finding of a low initial marrow cellularity (P < .05). This study finds that continuous intravenous infusion of LDARA-C for ANLL can achieve response rates comparable to standard induction programs in a subset of patients traditionally defined as have a poor prognosis.

AB - There is currently little experience using a continuous intravenous infusion of low-dose cytosine arabinoside (LDARA-C) in the treatment of acute nonlymphocytic leukemia (ANLL). We report the results in 12 patients with ANLL described as either relapsed ANLL, ANLL with a preceding myelodysplastic phase, or ANLL in the elderly treated with 14 days of continuous intravenous LDARA-C (20 mg/m2/day). Complete responses (CR) were seen in five patients (42%) and partial responses (PR) in three patients (25%). Treatment resulted in overall and clonal cytoreduction, which was evident by serial bone marrow exams and bone marrow cytogenetic analysis. The ability to obtain a CR correlated with the finding of a low initial marrow cellularity (P < .05). This study finds that continuous intravenous infusion of LDARA-C for ANLL can achieve response rates comparable to standard induction programs in a subset of patients traditionally defined as have a poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0023811921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023811921&partnerID=8YFLogxK

M3 - Article

C2 - 3189306

AN - SCOPUS:0023811921

VL - 29

SP - 79

EP - 84

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -